Among these patients, 97 (38.95%) had luminal subtype breast cancer, 82 (32.93%) had HER2-positive subtype breast cancer, and 70 (28.11%) had triple-negative breast cancer (TNBC). Here, ERBB2 is linked to breast carcinoma.